Windtree Therapeutics (WINT) Competitors $0.31 +0.01 (+3.52%) (As of 09:02 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends WINT vs. PMCB, TSBX, BCDA, KLTO, CERO, COEP, EVAX, ONVO, FRTX, and ALBTShould you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include PharmaCyte Biotech (PMCB), Turnstone Biologics (TSBX), BioCardia (BCDA), Klotho Neurosciences (KLTO), CERo Therapeutics (CERO), Coeptis Therapeutics (COEP), Evaxion Biotech A/S (EVAX), Organovo (ONVO), Fresh Tracks Therapeutics (FRTX), and Avalon GloboCare (ALBT). These companies are all part of the "biological products, except diagnostic" industry. Windtree Therapeutics vs. PharmaCyte Biotech Turnstone Biologics BioCardia Klotho Neurosciences CERo Therapeutics Coeptis Therapeutics Evaxion Biotech A/S Organovo Fresh Tracks Therapeutics Avalon GloboCare Windtree Therapeutics (NASDAQ:WINT) and PharmaCyte Biotech (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership. Do analysts rate WINT or PMCB? Windtree Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 2,125.76%. Given Windtree Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Windtree Therapeutics is more favorable than PharmaCyte Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Windtree Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00PharmaCyte Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, WINT or PMCB? Windtree Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Is WINT or PMCB more profitable? PharmaCyte Biotech's return on equity of 1.38% beat Windtree Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Windtree TherapeuticsN/A -362.76% -79.65% PharmaCyte Biotech N/A 1.38%0.71% Does the MarketBeat Community believe in WINT or PMCB? Windtree Therapeutics received 3 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformWindtree TherapeuticsOutperform Votes342.86% Underperform Votes457.14% PharmaCyte BiotechN/AN/A Which has higher valuation & earnings, WINT or PMCB? Windtree Therapeutics is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWindtree TherapeuticsN/AN/A-$20.29M-$16.47-0.02PharmaCyte BiotechN/AN/A$330K$0.532.94 Do insiders & institutionals have more ownership in WINT or PMCB? 29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are held by institutional investors. 0.9% of Windtree Therapeutics shares are held by insiders. Comparatively, 7.3% of PharmaCyte Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor WINT or PMCB? In the previous week, Windtree Therapeutics had 1 more articles in the media than PharmaCyte Biotech. MarketBeat recorded 1 mentions for Windtree Therapeutics and 0 mentions for PharmaCyte Biotech. Windtree Therapeutics' average media sentiment score of 0.64 beat PharmaCyte Biotech's score of 0.00 indicating that Windtree Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Windtree Therapeutics Positive PharmaCyte Biotech Neutral SummaryPharmaCyte Biotech beats Windtree Therapeutics on 7 of the 13 factors compared between the two stocks. Ad StocksToTradeLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!Click here to review Tim’s special Holiday offer before it’s too late. Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WINT vs. The Competition Export to ExcelMetricWindtree TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.83M$2.98B$5.23B$9.26BDividend YieldN/A1.90%5.11%4.27%P/E Ratio-0.0246.8086.9317.33Price / SalesN/A429.881,149.14123.93Price / CashN/A174.7643.2337.88Price / Book0.034.054.905.06Net Income-$20.29M-$42.00M$120.15M$225.13M7 Day Performance-1.78%3.60%2.99%4.21%1 Month Performance-48.43%-0.46%17.89%3.06%1 Year Performance-97.61%14.54%28.33%17.91% Windtree Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WINTWindtree Therapeutics2.3201 of 5 stars$0.31+3.5%$7.00+2,125.8%-97.6%$2.83MN/A-0.0220Short Interest ↑PMCBPharmaCyte Biotech1.0894 of 5 stars$1.63-0.3%N/A-32.5%$11.39MN/A2.482TSBXTurnstone Biologics3.0188 of 5 stars$0.45-8.2%$2.13+371.2%-83.8%$10.43M$19.31M-0.1482Gap UpBCDABioCardia3.7803 of 5 stars$2.05+4.3%$25.00+1,116.7%-76.2%$9.42M$71,000.00-0.4916Short Interest ↓Positive NewsGap DownKLTOKlotho NeurosciencesN/A$0.43-1.3%N/AN/A$9.12MN/A0.00N/AGap DownCEROCERo TherapeuticsN/A$0.05-7.5%N/AN/A$7.80MN/A0.008Short Interest ↑Gap DownCOEPCoeptis Therapeutics0.9784 of 5 stars$0.14+1.8%N/A-74.3%$5.92M$80,000.00-0.502News CoverageEVAXEvaxion Biotech A/S2.2516 of 5 stars$0.91-1.6%$11.00+1,115.5%-88.1%$5.31M$3.30M-3.1249Short Interest ↑ONVOOrganovo0.3177 of 5 stars$0.34-6.9%N/A-70.2%$5.15M$103,000.00-0.3220FRTXFresh Tracks TherapeuticsN/A$0.74+0.3%N/A-7.5%$4.44M$10.06M-0.5320ALBTAvalon GloboCare0.4055 of 5 stars$3.71+8.5%N/A-48.9%$4.06M$1.31M-0.195Short Interest ↑News Coverage Related Companies and Tools Related Companies PMCB Competitors TSBX Competitors BCDA Competitors KLTO Competitors CERO Competitors COEP Competitors EVAX Competitors ONVO Competitors FRTX Competitors ALBT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:WINT) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
